Figure - PMC

Skip to main content

An official website of the United States government

Here's how you know

Here's how you know

Official websites use .gov
A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS
A lock ( ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

View full-text article in PMC

. 2023 Apr 26;16:1193–1205. doi: 10.2147/DMSO.S407177

Search in PMC
Search in PubMed
View in NLM Catalog
Add to search

© 2023 Ren et al.

This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms (https://www.dovepress.com/terms.php).

PMC Copyright notice

BA suppresses HG-induced p65 nuclear translocation in HK-2 cells by the SphK1/S1P pathway. (A and B) HK-2 cells transfected with ov-SphK1 or ov-SphK1+si-S1P were treated with HG or HG+BA. (A) NF-κB p65 protein levels in the nucleus and cytoplasm were detected by immunoblotting assay, with Lamin B and GAPDH as the nuclear and cytoplasmic controls, respectively. (B) Quantitative analysis of NF-κB p65 protein levels in the nucleus and cytoplasm. **P<0.01 and ***P<0.001 vs control; ^##P<0.01 and ^###P<0.001 vs HG treatment; ^&&P<0.01 and ^&&&P<0.001 vs HG+BA treatment; ^{^}P<0.05 and ^{^^^}P<0.001 vs ov-SphK1+HG+BA treatment.